Eli Lilly 2012 Annual Report Download - page 12

Download and view the complete annual report

Please find page 12 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

10
Ixekizumab
psoriasis
Evacetrapib
atherosclerosis
Baricitinib
rheumatoid
arthritis
TGF-ß R1
inhibitor
cancer
TGF-ß MAb
chronic kidney
disease
Gem prodrug
cancer
p38 MAPK
inhibitor I
cancer
p13/mTOR
inhibitor
cancer
Notch inhibitor
cancer
Hepcidin MAb
anemia
Ferroportin
MAb
anemia
cardiovascular
disease
chronic kidney
disease
RON MAb
cancer
VEGFR3 MAb
cancer
CSF-1R MAb
cancer
cancer
c-Met inhibitor
cancer
p70/AKT
inhibitor
cancer
FGFR inhibitor
cancer
p38 MAPK
inhibitor II
cancer
11ßHSD1
inhibitor
diabetes
Gluc-R
antagonist
diabetes
Blosozumab
osteoporosis
ß-secretase
inhibitor
Alzheimer’s
migraine
prevention
depression
Litronesib
cancer
Chk1 inhibitor
cancer
c-Met MAb
cancer
CDK 4/6
inhibitor
cancer
Hedgehog
antagonist
cancer
JAK2 inhibitor
cancer
GSK3
cancer
cancer
Liprotamase
exocrine
pancreatic
insuciency
Icrucumab
cancer
diabetes
diabetes
diabetes
diabetes
diabetes
cognitive impair.
schizophrenia
bipolar
disorder
osteoarthritis
Pomaglumetad
CNS disorder
PHASE I PHASE III
PHASE I PHASE III REGULATORY
REVIEW
Florbetapir
ß-amyloid
imaging
FDA
APPROVED
cardiovascular
disease
osteoarthritis
diabetes
GP75 MAb
cancer
Survivin ASO
cancer
mGlu2 PotCys
migraine preven-
tion
elF-4E ASO
cancer
PHASE II
PHASE II
Olaratumab
cancer
depression
insomnia
obesity Tasisulam
cancer
IL-1 ß MAb
cardiovascular
disease
CXCR4 peptide
inhibitor
cancer
Pipeline of Molecules in Clinical Development
Information is current as of February 15, 2013. The search for new medicines is risky
and uncertain, and there are no guarantees. Remaining scientic and regulatory
hurdles may cause pipeline compounds to be delayed or to fail to reach the market.
New Chemical Entity
New Biotech Entity
Movement since 2011 Annual Report:
Achieved Milestone
Attrition
*Commercial Collaboration
Chk1 inhibitor
cancer
MR antagonist
chronic kidney
disease
Myostatin MAb
disuse atrophy
Cixutumumab
cancer
Empagliozin*
diabetes
New Insulin
Glargine
Product*
diabetes
Novel Basal
Insulin Analog
diabetes
Solanezumab
Alzheimer’s
Edivoxetine
depression
Tabalumab
lupus
Ramucirumab
solid tumors
Necitumumab
squamous
non-small cell
lung cancer
Enzastaurin
diuse large
ß-cell lymphoma
Dulaglutide
diabetes
NOTCH
inhibitor
cancer
diabetes
The Lilly pipeline currently
includes 64 molecules in clinical
development. Since our last annual
report, 10 new molecules advanced
into Phase I testing (including one
that has been terminated), eight
molecules advanced into Phase II
testing, two molecules advanced
into Phase III testing, and we
launched one new imaging agent.
We terminated development of
13 molecules and discontinued
specic indications for tabalumab
and pomaglumetad methionil
in Phase III. Tabalumab is still
being investigated in Phase III for
lupus while earlier-phase testing
continues for pomaglumetad. Our
Phase III portfolio is the largest
in the history of the company and
now includes eight biotech entities
and ve new chemical entities.
Additional information and
updates are available on the
Lilly Interactive Pipeline at
www.lilly.com.
In 2012, Elanco delivered 11
key approvals and more than
100 regional approvals. This
included products that augment
the company’s companion animal
parasiticide franchise, a new
Elanco product in companion
animal therapeutics, and products
that will enhance food animals’
productivity as well as food safety.
chronic kidney
disease